Scheriproct N Cream
Scheriproct N Cream is used for the treatment of internal and external haemorrhoids, Haemorrhoids post-partum, Anal pruritus, peri-anal eczema, anal fissures and proctitis, Post-haemorrhoidectomy application to relieve pain and discomfort
Scheriproct N Cream dosage
Cream Apply bid or tid for the 1st few days of treatment. Supp Insert 1 supp bid deep into the anus or tid for severe cases. Duration: Do not exceed 4 wk.
Scheriproct N Cream interactions
May lead to loss of Prednisolone (Scheriproct N N)-induced adrenal suppression.
Coadministration may be followed by cardiac enlargement and CHF.
Coadministration may produce severe weakness in patients with myasthenia gravis. If possible, withdraw anticholinesterase agent 24 h prior to starting Prednisolone (Scheriproct N N).
Because Prednisolone (Scheriproct N N) may increase blood glucose concentrations, dose adjustments of antidiabetic agents may be required.
Aspirin and other salicylates, NSAIDs
Risk of GI bleeding may be increased. Salicylate clearance may be increased.
CYP3A4 inducers (eg, barbiturates, carbamazepine, phenytoin, rifampin)
Prednisolone (Scheriproct N N) metabolism may be increased, reducing Prednisolone (Scheriproct N N) plasma levels and necessitating an increase in dosage.
CYP3A4 inhibitors (eg, estrogens [eg, hormonal contraceptives], ketoconazole, macrolide antibiotics [eg, erythromycin])
Prednisolone (Scheriproct N N) metabolism may be decreased, increasing Prednisolone (Scheriproct N N) plasma levels and increasing the risk of adverse reactions.
Prednisolone (Scheriproct N N) clearance may be increased, reducing plasma levels and decreasing the efficacy.
Increased activity of cyclosporine and Prednisolone (Scheriproct N N) may occur. Convulsions have been reported with coadministration of corticosteroids and cyclosporine.
Because of possible hypokalemia, the risk of arrhythmias may be increased.
Isoniazid serum levels may be reduced, decreasing the efficacy.
Potassium-depleting agents (eg, amphotericin B, diuretics)
Risk of hypokalemia may be increased.
Toxoids and live or inactivated vaccines
Because of inhibition of antibody response, patients on prolonged Prednisolone (Scheriproct N N) therapy may exhibit a diminished response to toxoids and live or inactivated vaccines. Replication of some organisms contained in live attenuated vaccines may be potentiated.
Because data are conflicting, monitor coagulation indices frequently.
Scheriproct N Cream side effects
Long-term continuous treatment with topical corticosteroids should be avoided as far as possible as this may cause atrophic changes in the skin leading to thinning, loss of elasticity, dilatation of superficial blood vessels, telangiectasiae and ecchymoses. These changes are particularly likely to occur when occlusive dressings are used. Systemic absorption of topically applied corticosteroids may occur, particularly under the following conditions: when large quantities are used or when application is made to wide areas of the body, or to damaged skin; when potent topical corticosteroids are used, and when the occlusive dressing technique is applied. Depression of the hypothalamic-pituitary-adrenal axis with consequent suppression of the adrenal gland may occur. These effects are most likely to be severe in children. Growth may be retarded and a Cushingoid state may be produced. Benign intracranial hypertension has been rarely reported.
The application of local anaesthetics to the skin for prolonged periods or to extensive areas should be avoided as local anaesthetics are potent sensitisers and allergic reactions may occur.
Prolonged local use of aminoglycosides should be avoided as it may lead to skin sensitisation. Ototoxicity has occurred following the topical application of aminoglycosides to mucous membranes. Reversible nephrotoxicity may occur.
The symptoms of overdosage of aesculin are muscle twitching, lack of co-ordination, dilated pupils, vomiting, diarrhoea, paralysis and stupor.
The following special precaution is recommended: if a secondary microbial skin infection is present, suitable concomitant anti-microbial therapy should be instituted.
Scheriproct N contraindications
Hypersensitivity to any of the ingredients.
Viral infections, primary bacterial or fungal infections in the treatment area. Secondary infections of the skin in the absence of appropriate antiinfective therapy. Known sensitivity to local anaesthetics.
Corticosteroids have been shown to be teratogenic in animals following dermal application. As these agents are absorbed percutaneously, teratogenicity following topical application cannot be excluded. Therefore, this medicine should not be used during pregnancy.
The excretion of effective amounts of glucocorticoid with the breast milk is improbable. Peritonitis, fistulae, obstruction, perforation, infections.
Find more products for your Hemorrhoidal Disease here